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ABSTRACT
Group A streptococci (GAS) have been described frequently as an emerging cause of severe invasive
infections in population-based surveillance studies, whereas the descriptions of group B, C and G
streptococci (GBS, GCS and GGS) have been less frequent. Enhanced surveillance for invasive GAS,
GBS, GCS and GGS was performed in Denmark in 1999–2002. A detailed questionnaire was
completed for 1237 (98%) of 1260 invasive infections. GAS infections dominated (40%), followed by
GGS (32%), GBS (23%) and GCS (6%). Most (74%) patients had predisposing factors, and there
were no significant differences between the four serogroups when comparing the prevalence of
cancer, diabetes mellitus, chronic heart or lung diseases, immunodeficiency or alcohol abuse. The
overall case fatality rate at day 30 was 21%, increasing significantly to 59% for patients with
streptococcal toxic shock syndrome (STSS). STSS was significantly more frequent in GAS patients
(10%) than in GCS (4%), GBS (2%) and GGS (2%) patients. Regression analyses showed that,
despite a younger median age among GAS patients, the probability of developing septic shock and
mortality was significantly higher among GAS patients than among GBS and GGS patients. These
analyses showed no significant differences between GAS and GCS infections. Invasive infections
caused by GAS, GBS, GCS and GGS are still a major challenge for clinicians. Continued
epidemiological and microbiological surveillance is important to assess the development of these
infections and to improve preventative strategies.
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INTRODUCTION
b-Haemolytic streptococci (BHS) groups A, B, C
and G (GAS, GBS, GCS and GGS) are a transient
part of the normal flora of the pharynx, skin,
intestinal tract and vagina, and can cause a variety
of invasive and non-invasive infections [1–7]. It is
not possible to differentiate between invasive
infections caused by GAS, GBS, GCS or GGS solely
on the clinical presentation [1–7]. However, GBS
remain one of the most significant causes of
invasive neonatal infections during the period
before, during and after delivery [8]. GBS, together
with GCS and GGS, have also been described as
frequent invasive pathogens in elderly patients,
often in association with alcohol abuse, diabetes
mellitus, malignant diseases, and cardiac and
peripheral vascular diseases [6,7,9]. In comparison,
GAS have been described since the mid-1980s as an
emerging cause of potentially fatal infections, such
as necrotising fasciitis (NF), myositis and strepto-
coccal toxic shock syndrome (STSS), described
originally in healthy young individuals [10]. The
same severe clinical presentations have been des-
cribed subsequently for GBS, GCS and GGS in
several case series, but more often in elderly
patients with predisposing factors.
The emergence of severe GAS infections has
resulted in enhanced surveillance of invasive
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GAS infections in Europe, the USA and Canada
since 1986 [2,11–15]. In the present study, a
nationwide prospective surveillance, designed
originally for invasive GAS infections, was used
to monitor invasive infections caused by GAS,
GBS, GCS and GGS. The aim was to estimate the
incidence of these infections and to determine
the frequency of symptoms, predisposing factors,
clinical presentation, treatment, complications
and outcome, in order to delineate any differ-
ences between invasive infections caused by
GBS, GCS, GGS and GAS in the same area
during the same period.
MATERIALS AND METHODS
Surveillance and specimens
The Streptococcus Unit at the Statens Serum Institut (Copen-
hagen, Denmark) serves as the National Streptococcus Refer-
ence Centre. During the study period, invasive BHS (groups A,
B, C and G) isolates were submitted from patients admitted to
all hospitals in Denmark (population 5.3 million). The isolates
were received as pure isolates, on a voluntary basis, from all
Danish clinical microbiological departments. All invasive BHS
cultures from normally sterile sites (e.g., blood, cerebrospinal
fluid, synovial fluid, pleural fluid, ascites and tissue obtained
during surgery) between 1 January 1999 and 31 December 2002
were collected.
Based on information concerning the number of BHS-
positive blood cultures from ten of the 15 clinical microbiolo-
gical departments, the Streptococcus Unit received a constant
proportion of these blood isolates, which on average was 79%
for GAS, 58% for GBS, 56% for GCS and 66% for GGS (overall
average 72%).
Questionnaire
A detailed questionnaire (describing the characteristics of the
patient, the infection and the outcome) was completed by the
physician responsible for the treatment of each patient.
Standard information (age, gender, specimen, serogroup,
serotype, date of culture) was included in the statistical
analysis even if the questionnaire was not returned. Invasive
GBS infections in infants aged < 90 days were considered to be
a distinct clinical entity and were not included in this study.
Bacteraemia was defined as a clinical entity associated
with identification of BHS from blood culture without any
specified focus of the infection or complications. NF was
defined as necrosis of the fascia and tissue (excluding
muscle) and was included as a clinical diagnosis only. A
patient with septic shock was defined as a patient with
invasive BHS infection and a systolic blood pressure of
< 90 mm Hg (in adults). The definition of STSS was based on
a consensus definition [16], including identification of BHS
from a normally sterile site, septic shock and multi-organ
failure. An overall case fatality rate (CFR) was assessed at
day 1 after the specimen was obtained (1-day CFR; death
within day 0 and day 1 after specimen collection), as well as
a 30-day CFR.
In order to validate the survey, 41 (3%) of the patients’
files were read and the corresponding questionnaires were
completed by one of the authors; only insignificant differ-
ences between the two questionnaires were found. If a
patient had more than one episode of invasive GAS, GBS,
GCS or GGS infection during the period 1999–2002, the
second episode was only registered in the database if the
dates of the cultures were separated by > 30 days, or if the
second episode was caused by an isolate belonging to a
different serogroup. Date of death, or a confirmation that an
individual was alive on 1 March 2004, was obtained from
the Central Office of Civil Registration for all except nine
patients; five patients did not have a personal identification
number (i.e., tourists or recent immigrants) and were
excluded from the analyses of the CFRs, while four patients
were registered as missing or as having left Denmark before
1 March 2004. They were registered as alive, but their details
were noted when their registration at the Central Office of
Civil Registration ended.
Statistical analysis
Data from the survey were analysed by the SAS System v.
8.2 (SAS Institute, Cary, NC, USA). Spearman rank correla-
tion tests were performed to assess the correlation between
the annual incidence rates of GAS, GBS, GCS and GGS,
respectively, and the time (in years). For comparisons of
proportions between serogroups in relation to outcome of
the variables described in the questionnaire, chi-square tests,
adjusted for stratification with relation to age (grouped as
£ 40, 40–65 and > 65 years) and gender, were used. However,
in situations where outcomes of the response variable were
rare, an analogue exact test was conducted. Stratification
according to age and gender was used primarily because of
a significant difference in the age and gender distribution
between the serogroups. Furthermore, only women aged
< 40 years were included in the statistical analysis regarding
fever in relation to delivery, puerperal sepsis and recent
delivery.
For the comparison of age distributions between sero-
groups and other sub-populations of the data, Kruskal–
Wallis or Mann–Whitney rank sum tests were used. Two
logistic regression analyses were performed to determine
factors which were associated significantly with STSS and
septic shock without fulfilling the criteria of STSS [16].
Factors included in the analysis were: gender, age (grouped
as £ 40, 40–65 and > 65 years), serogroup, cancer, diabetes,
chronic heart or lung diseases, skin lesions, alcohol abuse
and immunodeficiency. In order to compare the survival
functions between the four serogroups £ 30 days after the
culture was obtained, a Cox proportional-hazards regression
analysis was performed. The following independent varia-
bles were included in the model: gender, age (no grouping),
serogroups, cancer, diabetes, chronic heart or lung diseases,
skin lesions, alcohol abuse and immunodeficiency. The
estimated survival function can be considered as a prognosis
of mortality when previous knowledge of the patient is
available. If a parameter was recorded as ‘unknown’, or the
registration was missing, data were not included in the
statistical analyses. A p value of £ 0.05 was considered to be
significant. Odds ratios and 95% CIs were calculated.
Incidence rates were calculated in terms of the inci-
dence ⁄ 100 000 inhabitants ⁄ year.
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RESULTS
Study period
Fig. 1 shows the incidence of invasive GAS
infections, together with the incidence curves of
GBS, GCS and GGS, for 1988–2002. The annual
incidence of invasive GAS infections showed
considerable variation, but statistical analysis
did not reveal a significant trend. The incidence
of GBS and GGS showed a constant increase in
the study period between 1999 and 2002, but this
almost paralleled the increase in the number of
blood cultures in the same period (data not
shown).
During the study period, the Streptococcus
Unit received 1263 BHS isolates. In total, 1260
episodes of invasive BHS infections from 1231
different patients were included in the study.
Twenty-seven patients had more than one BHS
isolate registered at the Streptococcus Unit (n = 59
isolates), with the second isolate from eight
patients belonging to a different serogroup than
the first isolate. The same serogroup was isolated
twice from 15 patients, on three occasions from
three patients, and on four occasions from one
patient. Three isolates (one GBS, one GCS and one
GGS) were discarded because there were
< 30 days between the dates of the successive
cultures. Questionnaires were received in respect
of 1237 (98.2%) of the 1260 episodes.
The distribution of invasive episodes among
the four serogroups is shown in Table 1. The
median age of the patients with invasive GAS
infections was 59.8 (range 0.4–97.4) years, com-
pared to 64.7 (range 0.4–95.8) years, 72.8 (range
1.4–94.6) years and 71.7 (range 0.3–99.6) years
among patients with GBS, GCS and GGS infec-
tions, respectively. The age distribution differed
between the four serogroups, as invasive episodes
involving GCS and GGS were significantly more
prevalent in the older age groups compared to
episodes involving both GAS and GBS (p 0.001).
Females constituted 268 (54.0%) of 491 patients
with GAS infections, compared to 141 (49.6%) of
274, 33 (44.0%) of 73 and 176 (43.5%) of 393
patients with GBS, GCS and GGS infections,
respectively. In the group of invasive GBS infec-
tions, there were significantly more female than
male patients in the younger age groups
(p £ 0.001), a tendency that was not found with
the other serogroups. The overall gender distri-
bution did not differ significantly between the
four serogroups.
Fig. 2 shows that the incidence of streptococcal
infections increased with increasing age, partic-
ularly after the age of 55 years for GAS, after
65 years for GBS and GGS infections, and a
decade later for GCS infections.
Predisposing factors
The questionnaire revealed that most patients
with invasive BHS infection had underlying
predisposing factors, and that the frequencies
differed significantly between the serogroups
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Fig. 1. Incidence ⁄ 100 000 inhabitants ⁄ year of invasive
infections caused by group A, B, C and G streptococci in
Denmark 1988–2002.
Table 1. Invasive group A, B, C and G streptococcal
infections in Denmark (1999–2002)
Isolates from
No (% of isolates)
GAS GBS GCS GGS
Blood 454 (91.5) 273 (95.8) 70 (92.1) 382 (94.1)
CSF 10 (2.0) 3 (1.1) 1 (1.3) 4 (1.0)
Other specimens 32 (6.5) 9 (3.2) 5 (6.6) 20 (4.9)
Total 496 (100) 285 (100) 76 (100) 406 (100)
GAS, group A streptococci; GBS, group B streptococci; GCS, group C streptococci;
GGS, group G streptococci; CSF, cerebrospinal fluid.
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Fig. 2. Incidence ⁄ 100 000 inhabitants ⁄year by age of inva-
sive infections caused by group A, B, C and G streptococci
in Denmark 1999–2002.
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(p 0.014; Table 2). Skin lesions were the most
frequent predisposing factor and were found
most often among patients with GAS infections
(p £ 0.001). Even excluding Caesarian sections,
GBS dominated BHS infections because of peri- or
post-operative procedures (p 0.010). Cancer was
the second most frequent predisposing factor, but
there was no significant difference between the
serogroups (p 0.129). Likewise, the data showed
no significant differences between the serogroups
in the prevalence of diabetes mellitus, chronic
heart or lung diseases, human immunodeficiency
virus or alcohol abuse.
Clinical aspects
The variety of infections associated with the four
serogroups is summarised in Table 3.
In total, 208 (17.8%) of 1167 episodes were
registered as septic shock; these occurred in 124
(26.9%) patients with GAS, 32 (12.1%) patients
with GBS, 12 (17.8%) patients with GCS and 40
(10.7%) patients with GGS (p £ 0.001). All four
serogroups caused STSS, which was identified in
68 (5.5%) of 1237 patients. Most (73.5%) of the STSS
patients were infected with GAS. Furthermore,
GAS was identified in 34 (75.6%) of the 45 patients
with NF. Nineteen (1.5%) patients had myositis,
again with a significant difference between the
serogroups (p 0.036), since 16 (84.2%) patients
were infected with GAS. For 381 (30.8%) patients,
clinicians recorded bacteraemia as the only diag-
nosis, and this occurred more frequently with GBS
infections (p £ 0.001).
Case fatality rates
During the first 30 days following collection of the
specimen, 21% of patients with invasive BHS
infections died (23% of patients infected with
GAS, 21% with GCS, 19% with GBS, and 18%
with GGS). Patients infected with GAS had a
significantly higher 1-day CFR (11%) compared
to patients infected with GBS or GGS (both 5%;
p £ 0.001); 9% of the GCS patients died within
1 day, with no significant difference between GCS
and GAS patients (p 0.296).
The hazard functions for 30-day case fatality
(or, equivalently, the 30-day survival functions),
as estimated by a Cox proportional-hazards
regression, were significantly lower for GBS
(p 0.007) and GGS (p £ 0.001) than for GAS
(Table 4). No significant difference was observed
between the 30-day hazard functions for GAS and
GCS. Table 4 also presents the significant 30-day
hazard functions for chronic heart or lung disease,
alcohol abuse, immunodeficiency and skin le-
sions.
Septic shock and STSS
Overall, 59% of patients with STSS died within
the 30-day period following the collection of
cultures, compared to 57% of patients with septic
shock without STSS, and 13% of the non-septic
Table 2. Predisposing factorsa for invasive infection with
group A, B, C and G streptococci in Denmark (1999–2002)
GAS
n = 472
%
GBS
n = 271
%
GCS
n = 72
%
GGS
n = 386
%
Overall
p value
Predisposing factor (‡ 1) 73.7 79.0 75.0 83.9b 0.014
Skin lesions 31.6 17.7b 33.3 36.5 £ 0.001
Peri- ⁄post-operative 3.4 9.2b 2.8 5.7 0.010
IDU 4.9 1.1c 1.4 3.6 0.007
Cancer 13.1 18.5 15.3 19.7 0.129
Diabetes mellitus 11.0 14.0 13.9 15.8 0.904
Chronic heart or lung disease 5.5 6.3 8.3 7.5 0.925
Alcohol abuse 9.3 12.2 6.9 11.4 0.573
Immune deficiencyd 8.3 12.6 13.9 10.1 0.168
NSAID 6.1 6.3 0.0 6.7 0.146
GAS, group A streptococci; GBS, group B streptococci, GCS, group C streptococci;
GGS, group G streptococci; IDU, intravenous drug use; NSAID, non-steroid anti-
inflammatory drugs.
aA patient can have more than one predisposing factor, and a patient can have more
than one episode of invasive streptococcal infection.
bp £ 0.01 relative to serogroup A.
cp £ 0.05 relative to serogroup A.
dIncludes patients positive for human immunodeficiency virus and those receiving
immunosuppressive treatment.
Table 3. Clinical manifestations and complications of
invasive infection with group A, B, C and G streptococci
in Denmark (1999–2002)
GAS
n = 487
%
GBS
n = 278
%
GCS
n = 75
%
GGS
n = 397
%
Overall
p value
Septic shock 26.9 12.1a 17.8b 10.7a £ 0.001
STSS 10.3 2.2 4.0 2.3a £ 0.001
NF 7.0 1.8a 2.7 1.0a £ 0.001
Myositis 3.3 0.4a 0 0.5a 0.036
Pneumonia 10.3 7.6 4.0 4.8a 0.002
Meningitis 4.5 2.9 1.3 3.3 0.542
Arthritis 4.1 6.1 5.3 10.3a 0.002
Erysipelas 20.1 8.3a 34.7b 33.8a £ 0.001
Bacteraemia only 27.1 41.7a 32.0 27.5 £ 0.001
Puerperal feverc 35.9 33.3 0 16.7 0.352
ICU 24.7 14.6a 15.1b 10.0a £ 0.001
Mechanical ventilation 14.2 6.3a 6.9 4.6a £ 0.001
Surgery 28.9 19.6a 13.7b 17.2a £ 0.001
Renal impairment 30.7 25.2b 27.0 22.6a £ 0.001
Hepatic impairment 30.2 21.6a 25.0 21.2a 0.006
Coagulator dysfunction 20.7 13.2a 18.5 10.2a £ 0.001
GAS, group A streptococci; GBS, group B streptococci; GCS, group C streptococci;
GGS, group G streptococci; STSS, streptococcal toxic shock syndrome; NF,
necrotising fasciitis; ICU, intensive care unit.
ap £ 0.01 relative to serogroup A.
bp £ 0.05 relative to serogroup A.
cComparison performed among females aged < 40 years (GAS, n = 78; GBS, n = 42;
GCS, n = 3; GGS, n = 12).
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shock patients. Table 5 presents the results of a
logistic regression analysis of factors associated
significantly with STSS, and a similar analysis of
factors associated significantly with septic shock
without fulfilling the STSS definition.
DISCUSSION
This study provides an overview of invasive GAS,
GBS, GCS and GGS infections in Denmark during
1999–2002, based on nationwide enhanced pros-
pective surveillance. The incidence rates obtained
reflect the minimum estimates of invasive BHS
disease, since national streptococcal surveillance
in Denmark is based on voluntary submission of
invasive isolates from the local clinical microbio-
logy departments. However, c. 72% of invasive
BHS isolates were received and 98% of question-
naires were submitted, and incidence rates from
the county of Northern Jutland in Denmark [17]
were similar to those in the present study.
No increase in invasive GAS infections was
identified during the study period (1999–2002).
The average annual incidence and fluctuating
pattern of invasive GAS infections were both
similar to those in previous reports [11,12]. There
was a three-fold increase in invasive GBS and
GGS infections in Denmark during 1988–2002,
and the incidence curves showed similarities with
the incidence curve of GAS until 1996. These
similarities may reflect improvements in meth-
odology or an overall increase in the number of
blood cultures analysed. The incidence curves for
invasive GBS and GGS were almost parallel
in 1988–2002. The reason for the continuous
increases since 1998 remains unclear, although
increased awareness or prolonged survival of
adults with underlying chronic diseases (diabetes
mellitus, cancer and heart disease) may be a
contributing factor [4–9,18–20]. The incidence of
GGS and the emerging trend of invasive GGS
infections, approaching and potentially surpass-
ing the incidence of invasive GAS infections, were
similar to those described elsewhere [20–22]. The
incidence of invasive GBS infections was lower
than that described in Europe and North America
[4,5,23], but was similar to the average annual
incidence in a recent surveillance study from
Finland [8]. This may be a consequence of the
moderate submission rate or may be caused by
variations in bacterial virulence, host susceptibil-
ity, socio-economic factors or demographic vari-
ations. Comparisons of the incidence of GCS
infection are almost impossible, since only two
studies have presented epidemiological data
[24,25].
The present study confirmed that GAS patients
are generally younger and associated less fre-
quently with predisposing factors when com-
pared to GBS, GCS and GGS patients [4–7,17–
20,25–27]. However, no significant differences in
the frequencies of cancer, diabetes mellitus, chro-
nic heart or lung diseases or alcohol abuse were
identified in the comparisons between the four
serogroups in the present study. As described
previously [2,4–7,9,17–20,22,25], skin was the
most common portal of entry, while skin and soft
tissue infections, together with bacteraemia with-
out focal symptoms, were the most prevalent
clinical presentations of invasive BHS infections.
Patients with invasive GBS infections were infec-
ted more often in association with surgical pro-
cedures, and were less likely than GAS patients to
Table 4. Cox proportional-hazards regression analysis of
factors associated with fatal outcome within 30 days after
invasive infection caused by group A, B, C and G
streptococci in Denmark (1999–2002)
Cox proportional-hazards regression
p value Hazard ratio (95% CI)
Age £ 0.001 –
GBS vs. GAS 0.007 0.63 (0.45–0.88)
GCS vs. GAS 0.247 0.73 (0.43–1.24)
GGS vs. GAS £ 0.001 0.52 (0.38–0.70)
CHLD £ 0.001 2.54 (1.53–3.32)
Alcohol abuse £ 0.001 2.38 (1.64–3.45)
Immune incompetencea 0.003 1.58 (1.17–2.14)
Skin lesions 0.019 0.70 (0.52–0.94)
GAS, group A streptococci; GBS, group B streptococci; GCS, group C streptococci;
GGS, group G streptococci; CHLD, chronic heart or lung diseases.
aIncludes patients positive for human immunodeficiency virus and those receiving
immunosuppressive treatment.
Table 5. Results of logistic regression analyses of predis-
posing factors associated with septic shock, with or
without streptococcal toxic shock syndrome, after invasive
infection caused by group A, B, C and G streptococci in
Denmark (1999–2002)
Septic shock including
STSS
Septic shock excluding
STSS
p value OR (95% CI) p value OR (95% CI)
GBS vs. GAS £ 0.001 0.19 (0.08–0.45) 0.005 0.50 (0.31–0.81)
GCS vs. GAS 0.101 0.37 (0.11–1.22) 0.530 0.80 (0.39–1.62)
GGS vs. GAS £ 0.001 0.20 (0.09–0.42) £ 0.001 0.35 (0.22–0.55)
Age – – £ 0.001 –
CHLD – – 0.005 2.42 (1.30–4.48)
Alcohol abuse – – £ 0.001 2.29 (1.35–3.90)
GAS, group A streptococci; GBS, group B streptococci; GCS, group C streptococci;
GGS, group G streptococci; CHLD, chronic heart or lung disease; STSS, strepto-
coccal toxic shock syndrome.
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have an impaired skin barrier (i.e., skin lesions or
intravenous drug users). In the present study,
most GBS infections were diagnosed as bacterae-
mia with an unknown focus of infection, and
more frequently than in previous reports [4,19]. In
contrast to GBS, GGS were associated particularly
with skin infections. Erysipelas was recorded
more frequently for patients with GCS and GGS
than for patients with GAS and GBS. Similarly,
cellulitis occurred in 60% of patients with inva-
sive GGS infections in a study from Israel [21].
This may reflect a new aspect of this clinical
entity, since erysipelas has been regarded tradi-
tionally as a specific kind of superficial cellulitis
caused predominantly by GAS [28,29].
Puerperal sepsis is regarded currently as a
minor problem, but the present results indicate
that clinicians should still suspect streptococcal
infections in relation to delivery, occurring either
sporadically or in clusters [30]. Endocarditis and
osteomyelitis have also been described among the
clinical manifestations of invasive streptococcal
infections [3,6,7,12,18,19,31], but these entities
were not included in the present prospective
survey. Neither was pneumonia, although it was
recorded by clinicians in 7% of cases, which
resulted in a frequency slightly lower than that
reported previously [5,6,20,25,26,32,33]. Pneu-
monia is not a diagnosis associated normally
with BHS, as it was in the pre-antibiotic era, but
there may be re-emergence of this entity [33].
However, there are obvious limitations in the
diagnosis, since no radiological confirmation was
obtained, and objective distinctions between BHS
pneumonia and invasive BHS disease complica-
ted by adult respiratory distress syndrome are
lacking.
From the clinicians’ point of view, it may be
difficult to distinguish between STSS and a
straightforward case of septic shock, as similar
CFRs were found, and these were comparable to
CFRs for septic shock caused by other pathogens
[34]. The case definition of STSS may identify
individuals with toxic septic shock, as well as
those who develop multi-organ failure when
subjected to the stress of sepsis without toxicity,
although this was not the intention of the con-
sensus definition [16]. Severe infections such as
septic shock (with or without STSS) and NF were
more likely to be caused by GAS than by GBS,
GCS and GGS. GAS was the only independent
predictor for the development of STSS, whereas
septic shock without STSS was associated with
increased age and predisposing factors such as
chronic heart or lung diseases and alcohol abuse,
as well as GAS. Moreover, GAS STSS patients
were younger than GAS patients with septic
shock without STSS, perhaps because a certain
level of immune response is required for progres-
sion of multi-organ failure involved in STSS. This
may be seen as analogous to the association
between the HLA class II allotype of infected
patients and disease progression; that is, the
allotype influences the in-vitro immune response
induced by streptococcal superantigens, and
thereby identifies high and low responders to
superantigens [35]. The elderly, with potential
immune senescence, or patients with immune
deficiency, are associated with poor prognosis for
other more obvious reasons [7]. Both the fre-
quency of GAS STSS and the 30-day CFR were
comparable with those in other studies [11,12].
The occurrence of STSS caused by GBS, GCS or
GGS has been reported primarily in case series
studies [36–42], but data from population-based
studies has not been presented previously in
comparison with GAS STSS.
NF was predominantly a disease caused by
GAS, and occurred at a frequency similar to that
in previous reports [12,31]. Since the present
surveillance study included primarily blood iso-
lates, with only a few isolates from surgical tissue,
the real prevalence will probably be higher
[11,43]. A large surveillance study of invasive
GBS infections [9] reported a GBS NF prevalence
of 0.3%, compared with 2% of patients with GBS
in the present study and elsewhere [19]. In the
present study, NF occurred in 3% and 1% of the
patients with GCS and GGS infections, respect-
ively. NF caused by GBS, GCS and GGS has been
described previously in several case series
[36,41,44–47]. As the clinical presentations of NF
and STSS caused by GBS, GCS and GGS are
indistinguishable from those caused by GAS, the
underlying mechanisms are likely to be related.
Some researchers consider that the possible acqui-
sition of GAS-related virulence genes, especially
by GGS, is consistent with the hypothesis
that GGS may be an emerging pathogen with
increased virulence potential [48,49].
The overall 21% CFR for invasive BHS infec-
tions was similar to that found previously in
population-based studies [2,7,9,17,18,20,26],
although other studies have reported lower fig-
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ures [4,19]. Because information regarding patient
mortality was obtained from the Central Office of
Civil Registration, the cause of fatalities, and the
link with BHS infection, was not investigated.
However, it has been estimated that c. 90% of
deaths which occur within 30 days are related
directly to the infection [22]. In addition to the
serotype involved, the prognosis of invasive BHS
infection was associated independently with
increased age and the precise predisposing factor
(i.e., chronic heart or lung diseases, alcohol abuse
or immunodeficiency). However, patients with
skin lesions were associated negatively with
death compared to patients without skin lesions.
This was interpreted as a difference between
patients with primary bacteraemia (no skin
lesions and without any obvious focus of the
initial infection) and secondary bacteraemia (with
skin lesions and therefore an obvious site of initial
infection).
In conclusion, invasive infections caused by
BHS remain a major challenge for clinicians. The
clinical manifestations vary, and the CFR of 21%
increases to c. 60% in patients with septic shock.
An ageing population, and progress in the treat-
ment of chronic medical conditions, provides an
expanding number of patients at risk of invasive
BHS. In order to improve preventive strategies
and therapeutic procedures, further investigation
of the interactions between host and pathogen is
needed. Continued epidemiological and micro-
biological surveillance is important to assess the
future development of invasive BHS infections.
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